emylcamate

Emylcamate is a small molecule anxiolytic and muscle relaxant of the carbamate ester class. It was developed and marketed in the early 1960s under the brand name Striatran by Merck for the treatment of anxiety and tension[1][6][7]. Emylcamate acts primarily as a central nervous system depressant by enhancing GABAergic activity; specifically, it is a positive allosteric modulator at Gamma-aminobutyric acid receptor subunit alpha (GABA-A receptor), increasing inhibitory neurotransmission to produce sedative and anxiolytic effects[5]. Preclinical studies indicated that emylcamate had greater potency and faster onset than meprobamate, but it was eventually replaced by meprobamate in clinical use[1][6]. The drug is no longer prescribed.

Brand names

Striatran

Other names

3-methylpentan-3-yl carbamate3-methyl-3-pentanol carbamateEmilcamatoEmylcamat